Molecular Partners AG (MOLN)
MOLN Stock Price Chart
Explore Molecular Partners AG interactive price chart. Choose custom timeframes to analyze MOLN price movements and trends.
MOLN Company Profile
Discover essential business fundamentals and corporate details for Molecular Partners AG (MOLN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Jun 2021
Employees
158.00
CEO
Patrick Amstutz
Description
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
MOLN Financial Timeline
Browse a chronological timeline of Molecular Partners AG corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 24 Aug 2026
EPS estimate is -$0.45.
Earnings released on 12 May 2026
EPS came in at -$0.45 falling short of the estimated -$0.38 by -18.42%.
Earnings released on 12 Mar 2026
EPS came in at -$0.41 falling short of the estimated -$0.40 by -2.47%.
Earnings released on 30 Oct 2025
EPS came in at -$0.41 surpassing the estimated -$0.46 by +10.87%.
Earnings released on 25 Aug 2025
EPS came in at -$0.67 falling short of the estimated -$0.53 by -26.42%.
Earnings released on 15 May 2025
EPS came in at -$0.50 falling short of the estimated -$0.42 by -18.64%.
Earnings released on 6 Mar 2025
EPS came in at -$0.34 surpassing the estimated -$0.44 by +22.73%.
Earnings released on 31 Oct 2024
EPS came in at -$0.57 surpassing the estimated -$0.63 by +9.52%, while revenue for the quarter reached $810.23k , beating expectations by +1.28%.
Earnings released on 26 Aug 2024
EPS came in at -$0.51 surpassing the estimated -$1.26 by +59.52%, while revenue for the quarter reached $1.73m , beating expectations by +95.70%.
Earnings released on 16 May 2024
EPS came in at -$0.39 , while revenue for the quarter reached $3.02m , beating expectations by +1.28%.
Earnings released on 14 Mar 2024
EPS came in at -$0.68 surpassing the estimated -$0.97 by +29.90%, while revenue for the quarter reached $1.21m , missing expectations by -31.08%.
Earnings released on 26 Oct 2023
EPS came in at -$0.40 , while revenue for the quarter reached $2.77m , beating expectations by +81.91%.
Earnings released on 23 Aug 2023
EPS came in at -$0.55 , while revenue for the quarter reached $462.67k , missing expectations by -74.14%.
Earnings released on 12 May 2023
EPS came in at -$0.49 , while revenue for the quarter reached $3.33m , beating expectations by +84.88%.
Earnings released on 9 Mar 2023
EPS came in at -$0.56 falling short of the estimated $0.90 by -162.22%, while revenue for the quarter reached $2.91m , missing expectations by -35.53%.
Earnings released on 27 Oct 2022
EPS came in at -$0.42 surpassing the estimated -$0.66 by +35.97%, while revenue for the quarter reached $2.37m , missing expectations by -28.52%.
Earnings released on 25 Aug 2022
EPS came in at -$0.15 surpassing the estimated -$0.66 by +77.13%, while revenue for the quarter reached $12.26m , beating expectations by +0.20%.
Earnings released on 12 May 2022
EPS came in at $4.99 surpassing the estimated -$0.66 by +860.76%, while revenue for the quarter reached $186.63m , beating expectations by +4.32%.
Earnings released on 15 Mar 2022
EPS came in at -$0.56 surpassing the estimated -$1.04 by +46.15%, while revenue for the quarter reached $14.56m , missing expectations by -5.03%.
Earnings released on 28 Oct 2021
EPS came in at -$0.41 , while revenue for the quarter reached $3.79m .
Earnings released on 26 Aug 2021
EPS came in at -$0.60 , while revenue for the quarter reached $3.48m .
MOLN Stock Performance
Access detailed MOLN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
